Intravenous Levodopa
( DrugBank: - / KEGG DRUG: - )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
6 | パーキンソン病 | 9 |
6. パーキンソン病
臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
Showing 1 to 9 of 9 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04912115 (ClinicalTrials.gov) | October 5, 202120211005 | 25/5/202120210525 | Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dysk ... | A Multi-Center, Phase II, Randomized, Double-Blind, Prospective, Active Placebo- Controlled Trial of Sub-Anesthetic Intravenous Infusion of Ketamine to Treat Levodopa- Induced Dyskinesia in Subjects With Parkinson's Disease A Multi-Center, Phase II, Randomized, Double-Blind, Prospective, Active Placebo- Controlled Trial of ... | Dyskinesias;Movement Disorders;Central Nervous System Diseases;Nervous System Diseases;Neurologic Manifestations Dyskinesias;Movement Disorders;Central Nervous System Diseases;Nervous System Diseases;Neurologic Ma ... | Drug: Ketamine;Drug: Midazolam | PharmaTher Inc. | NULL | Suspended | 30 Years | 85 Years | All | 30 | Phase 2 | United States |
2 | NCT04064294 (ClinicalTrials.gov) | June 1, 201920190601 | 19/8/201920190819 | Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors | Preventing Levodopa Induced Dyskinesia in Parkinson?s Disease With Statins | Parkinson Disease;Dyskinesia, Drug-Induced | Drug: Intravenous Infusion | VA Office of Research and Development | Oregon Health and Science University | Recruiting | 50 Years | N/A | All | 120 | United States | |
3 | NCT03419806 (ClinicalTrials.gov) | February 16, 201820180216 | 10/1/201820180110 | Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa in Patients With Parkinson's Disease Study Comparing Intravenousand Subcutaneous Infudopa With Intestinal Duodopa in Patients With Parkin ... | Levodopa Pharmacokinetics in Patients With Parkinson's Disease and Symptom Fluctuation: A Phase I, Open-label, Randomized, Multicentre, Crossover Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa LevodopaPharmacokinetics in Patients With Parkinson's Disease and Symptom Fluctuation: A Phase I, Op ... | Parkinson Disease | Drug: Infudopa i.v.;Drug: Infudopa s.c.;Drug: LCIG (Duodopa) | Vastra Gotaland Region | The Swedish Research Council;Dizlin Medical Design AB;Göteborg University | Completed | 30 Years | N/A | All | 25 | Phase 1 | Sweden |
4 | NCT01003002 (ClinicalTrials.gov) | December 201020101200 | 27/10/200920091027 | Natural History of Levodopa-Induced Dyskinesia (LID) | Determining the Natural History of Levodopa-Induced Dyskinesia (LID) | Parkinson's Disease | Drug: Levodopa (delivered intravenously) | Oregon Health and Science University | Oregon Clinical and Translational Research Institute | Withdrawn | 21 Years | 100 Years | Both | 0 | N/A | United States |
5 | NCT00605553 (ClinicalTrials.gov) | April 200820080400 | 15/1/200820080115 | Study to Evaluate SYN115 in Parkinson's Disease | A Randomized, Double-blind, Placebo Controlled, Two-way Cross-over Study to Explore the Effects of 7 Days of Dosing With SYN115 20 mg p.o. BID or 60 mg p.o. BID on Clinical and fMRI Response to Intravenous Levodopa in Patients With Mild to Moderate Parkinson's Disease A Randomized, Double-blind, Placebo Controlled, Two-way Cross-over Study to Explore the Effects of 7 ... | Parkinson's Disease | Drug: Placebo;Drug: Tozadenant | Biotie Therapies Inc. | NULL | Completed | 40 Years | 75 Years | All | 30 | Phase 2 | United States |
6 | NCT00467597 (ClinicalTrials.gov) | April 200620060400 | 27/4/200720070427 | Developing Objective Measures of Levodopa Induced Dyskinesia: (Study 1) | Quantification of Levodopa Induced Dyskinesia in Parkinson Disease: Developing Objective Measures of Levodopa Induced Dyskinesia (Study One) Quantification of LevodopaInduced Dyskinesia in Parkinson Disease: Developing Objective Measures of ... | Dyskinesias;Movement Disorders;Parkinson Disease | Drug: Levodopa (delivered intravenously) | VA Office of Research and Development | Oregon Health and Science University | Completed | 21 Years | N/A | All | 36 | N/A | United States |
7 | NCT00089622 (ClinicalTrials.gov) | August 4, 200420040804 | 6/8/200420040806 | Lisuride Patch to Treat Parkinson's Disease | Transcutaneous Lisuride Therapy of Parkinson's Disease | Parkinson Disease | Drug: Intravenous Levodopa;Drug: Lisuride Transdermal System | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | 40 Years | 80 Years | All | 40 | Phase 2 | United States |
8 | NCT00086294 (ClinicalTrials.gov) | June 25, 200420040625 | 29/6/200420040629 | ACP-103 to Treat Parkinson's Disease | 5HT2A/C Serotonin Blockade in Parkinson's Disease | Parkinson's Disease;Dyskinesias | Drug: Intravenous Levodopa;Drug: ACP-103 | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | 30 Years | 80 Years | All | 40 | Phase 2 | United States |
9 | NCT00076674 (ClinicalTrials.gov) | January 200420040100 | 28/1/200420040128 | Levetiracetam Treatment of L-dopa Induced Dyskinesias | Levetiracetam Treatment of L-dopa Induced Dyskinesias | Dyskinesias;Parkinson Disease | Drug: Intravenous Levodopa | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | N/A | N/A | Both | 40 | Phase 2 | United States |